JPRN-UMIN000015972已完成2 期
A Phase II trial of Dose adjusted EPOCH and Rituximab therapy for newly-diagnosed DLBCL with C-MYC rearrangement - A Phase II trial of DA-EPOCH-R therapy for newly-diagnosed DLBCL with C-MYC rearrangement
Kanagawa Clinical Oncology study Group0 个研究点目标入组 34 人开始时间: 2014年12月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) History of glaucoma (2) Uncontrollable diabetes mellitus (3) Uncontrollable hypertension (4) Coronary artery disease under treatment; cardiomyopathy, heart failure, or arrhythmia treated with anti-arrhythmic (5) HBs antigen positive (6) HCV antibody positive (7) HIV antibody positive (8) Interstitial pneumonia, pulmonary fibrosis (9) Severe infection (10) Liver cirrhosis (11) Other active malignancies; history of lymphoma, myelodysplastic syndrome, or leukemia (12) Pregnant, possible pregnant, or breastfeeding woman (13) Severe psychosis (14) Under systemic corticosteroid therapy
研究者
相似试验
已完成
2 期
A Phase II trial of DA-EPOCH And Rituximab with HD-MTX therapy for newly-diagnosed DLBCL with CD5 expression (PEARL5 study)CD5-positive diffuse large B-cell lymphomaJPRN-UMIN000008507CD5+ DLBCL Treatment Study Group47
已完成
2 期
PEARL5 studyJPRN-jRCTs041180159Yamaguchi Motoko45
已完成
2 期
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaAIDS-Related Burkitt LymphomaAtypical Burkitt/Burkitt-Like LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRecurrent Acute Lymphoblastic LeukemiaRecurrent Burkitt LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Burkitt LymphomaNCT02199184M.D. Anderson Cancer Center14
已完成
2 期
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell LymphomaLymphoma, Mantle CellMantle Cell LymphomaNCT00114738National Cancer Institute (NCI)53
Unknown
2 期
Trial of DA-EPOCH Regimen for NHL With HLHNHL With Hemophagocytic LymphohistiocytosisNCT01818908The First Affiliated Hospital with Nanjing Medical University50